Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PREP | P48147 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139033 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL28510226 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL29378245 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL29549607 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL29503800 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL119560 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL1002927 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL118354 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL30564473 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 | |
| SCHEMBL29503770 | 0.95 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2PREPRAB9AFABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119708197-A | Ruitalu Process for producing peptide | 深圳翰宇药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119708196-A | Tenipout peptide synthesis method | 深圳翰宇药业股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119350469-A | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119350471-A | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118147106-A | Preparation methods of enzyme, complex enzyme, immobilized enzyme and Tirzepatide | 深圳瑞德林生物技术有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118005767-A | Method for preparing Tirzepatide by combining solid and liquid | 柏佳薇(深圳)生物科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-115327010-B | Fmoc-L-Pro-OH.H 2 Method for measuring content of O and related impurities | 泰州兴普泰生物制药有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-116355041-A | Fmoc-L-Pro-L-Pro-OH preparation method | 上海合全药物研发有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-115327010-A | Fmoc-L-Pro-OH.H 2 Method for measuring content of O and related impurities | 泰州兴普泰生物制药有限公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2026107423-A1 | ORAL PEPTIDES AND USES THEREOF FOR WEIGHT LOSS, WEIGHT MAINTENANCE, AND MANAGEMENT OF METABOLIC CONDITIONS | METSERA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-120943886-B | Synthesis method of tripeptide Fmoc-Pro-Pro-Pro-OH | 浙江肽昇生物医药有限公司 | 2026-01-30 | — | — | CN | disclosed |
| EP-3774838-B1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-08-10 | — | — | EP | disclosed |
| CN-108697767-B | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | 安塔罗斯医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111499719-B | Method for synthesizing pramlintide | 杭州固拓生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | ALDH1A1 2545/4885SMN1; SMN2 2204/4885PREP 541/4885 |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | GLP1R, GIPR, GRPR | ALDH1A1 3254/4885SMN1; SMN2 2039/4885PREP 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.